Durysta Generic: When Will Generic Bimatoprost Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Durysta Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? During 2041 Sometime that year Why then?
- Has the FDA approved a generic? February 2015 9 companies approved
- When does the brand’s protection end? October 2034 The last of 7 listed patents
- Can you buy a generic today? Yes 15 companies list one
Dr. Brian Staiger Explains
PharmD, BCPS · Clinical pharmacistIt already is. A generic bimatoprost is listed for sale by 15 companies, so ask your pharmacy whether it can fill your prescription with one.
Why 2041?
No generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early. We rate it probable: more likely than not, but it can still move.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Durysta, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Durysta by the Numbers
- Reason
- Not yet clearNo generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- $34M a yearSmaller seller
- FDA approved 2020 March 2020 FDA Orange Book
- Patents listed 7 last runs to October 2034 FDA Orange Book
- Generics FDA-approved 9 companies, the first approved February 2015 FDA Orange Book
- Medicare Part D spent $2M in 2025, for 514 people CMS Part D Spending by Drug
- Medicaid prescriptions 507 in the last four reported quarters, $882.5K CMS Medicaid drug utilization, to Q1 2026
Durysta’s Road to a Generic
Durysta has had the market to itself since the FDA approved it in March 2020 (Abbvie Inc). Its 7 listed patents run to October 2034.
The first generic of Durysta is expected sometime in 2041.
No generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Durysta Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Durysta’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 9,149,428 | The product’s formulation | December 2026 | Active |
| 10,441,543 | The product’s formulation | December 2026 | Active |
| 8,206,737 | A way of using it (U-2759) | April 2027 | Active |
| 7,799,336 | The product’s formulation | April 2029 | Active |
| 8,629,185 | The active ingredient; the product’s formulation | July 2031 | Active |
| 9,492,316 | The product’s formulation | October 2034 | Active |
| 9,980,974 | A way of using it (U-2759) | October 2034 | Active |
Source: FDA Orange Book, application 211911. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Bimatoprost
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No application count is on record for Durysta, but the FDA has already approved 9 companies (step 2), and every approval starts with an application.
The FDA has tentatively approved 5 companies’ generics, listed below. A tentative approval means the generic is ready, but a patent or exclusivity still stops the FDA from giving it final approval.
Approved by the FDA
The FDA has approved generic versions from 9 companies, the first in February 2015. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic bimatoprost is listed for sale by 15 companies. Ask your pharmacy whether it can fill your prescription with it.
Akorn, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals NY LLC, Apotex Corp., Aurobindo Pharma Limited and 9 more
| Company | Tentatively approved |
|---|---|
| Sandoz | April 2011 |
| Sandoz Inc | August 2014 |
| Apotex Inc | January 2015 |
| Gland Pharma Ltd | October 2019 |
| Micro Labs Ltd India | May 2021 |
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Sandoz Inc | May 2015 | 0.03% | AT |
| Apotex Inc | July 2015 | 0.03% | AT |
| Gland Pharma Ltd | March 2019 | 0.03% | AT |
| Alembic Pharmaceuticals Ltd | April 2019 | 0.03% | AT |
| Somerset Therapeutics LLC | June 2019 | 0.03% | AT |
| Micro Labs Ltd | September 2020 | 0.03% | AT |
| Eugia Pharma Specialities Ltd | October 2022 | 0.03% | AT |
| Mankind Pharma Ltd | March 2025 | 0.01% | AB |
| Amneal Eu Ltd | September 2025 | 0.01% | AB |
| Lupin Ltd discontinued | February 2015 | 0.03% | – |
| Hikma Pharmaceuticals USA Inc discontinued | November 2018 | 0.03% | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Durysta Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Durysta, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Durysta
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Durysta, before manufacturer rebates.
- $331K
- January to March 2026, the latest CMS has posted
For 90 people, about $3,637 per prescription fill - $2M
- 2025, the whole year
For 514 people, about $3,481 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $331,005 | 90 | $3,637.42 |
| 2025 | $2,026,172 | 514 | $3,481.39 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Durysta only, so no generic is counted in it. What CMS says it is used for: Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness.
Medicaid Prescriptions by Quarter
507 prescriptions in the four quarters to Q1 2026, $882.5K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 73 | $139,069 |
| Q4 2025 | 141 | $261,467 |
| Q3 2025 | 184 | $295,588 |
| Q2 2025 | 109 | $186,414 |
| Q1 2025 | 99 | $169,860 |
Source: CMS Medicaid State Drug Utilization Data, over Durysta’s own package codes.
Durysta Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 10MCG | Implant | Ophthalmic | March 2020 | Prescription reference product |
Source: FDA Orange Book, Abbvie Inc. Listed for sale today by Allergan, Inc. (FDA NDC Directory).
Durysta NDC Codes and Packages
Each Durysta package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 00023-9652-01 | BIMATOPROST 10 ug/1 implant | pouch of 1 implant | Allergan, Inc. |
| 00023-9652-01 | BIMATOPROST 10 ug/1 implant | pouch of 1 implant | Allergan, Inc. |
| 00023-9652-03 | BIMATOPROST 10 ug/1 implant | pouch of 1 implant | Allergan, Inc. |
| 00023-9652-03 | BIMATOPROST 10 ug/1 implant | pouch of 1 implant | Allergan, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Durysta’s own FDA approval (NDA 211911) are listed, never a generic. Some codes belong to companies that repackage Durysta: it is the same medicine in a different package.
What a Generic Durysta Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Durysta
Is there a generic for Durysta right now?
Yes. The FDA NDC Directory lists a generic bimatoprost from 15 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Durysta go generic?
It already has. The FDA NDC Directory lists a generic bimatoprost from 15 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic bimatoprost be the same as Durysta?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. The FDA has already approved 9 companies to make a generic, and how many of them launch decides how far the price falls.
Has the FDA approved a generic Durysta?
Yes. The FDA Orange Book lists approved generic versions from 9 companies, the first approved in February 2015: Sandoz Inc, Apotex Inc, Gland Pharma Ltd, Alembic Pharmaceuticals Ltd and 5 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Durysta patent expire?
The FDA Orange Book lists 7 patents for Durysta; the last runs to October 2034. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (Sometime in 2041) weighs all of that.
Changes to This Projection
- First generic expected Sometime in 2041 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- ByvalsonNebivolol and ValsartanDuring 2026
- Lumify PFBrimonidine TartrateJuly to December 2027
- Trelegy ElliptaFluticasone Furoate, Umeclidinium Bromide, and Vilanterol TrifenatateApril 2031
- ZejulaNiraparib TosylateAugust 2031
- Furoscix ReadyFlowFurosemideJanuary 2040
- Purified CortrophinCorticotropinOctober 2043
About Durysta
- Generic name bimatoprost
- How it is taken In the eye
- Company Abbvie Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with D
- Have a question? A pharmacist answers, free. Ask about Durysta
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.